lyle mcdonald glp-1 Medications for Weight Loss: What You’re Not Being Told LYLE MCDONALD GLP-1 MASTERCLASS: A

doi: 10.1038/nm.2207

In clinical trials, weekly subcutaneous semaglutide at the 2.4 mg dose (the Wegovy formulation) produced a mean weight loss of approximately 14.9% of body weight over 68 weeks in the STEP 1 trial, compared with 2.4% for placebo

This appetite suppression is one of the main reasons tirzepatide works so well for weight loss

Staying at your current effective dose for a longer period can be a more strategic approach, especially if you are still experiencing appetite control without uncomfortable side effects

Deciding on B12 supplements during cancer treatment needs teamwork between you and your healthcare team